Comparison between Utilization of Botox Versus Fluticasone Furoate in Patients with Intermittent Allergic Rhinitis: A Randomized, Controlled Trial Pages 22-27

Diaa El Din Mohamed El Hennawi and Mohamed Rifaat Ahmed

Otolaryngology Unit, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

DOI: http://dx.doi.org/10.12970/2308-7978.2015.03.01.5

Abstract: Background: Allergic rhinitis is a common disease affects about 5 to 22% from general population. Botulinum toxin is a neurotoxic protein assumed to lead to symptomatic control of intermittent allergic rhinitis.

Objectives: To compare between utilization of botulinum toxin type A versus fluticasone furoate in treatment of intermittent allergic rhinitis.

Patients and Methods: A randomized clinical controlled trial study created on seventy two adult patients with intermittent allergic rhinitis divided into two groups; Group B (BTX-A) and Group F (fluticasone furoate).

Results: After one month the mean intensity of nasal symptoms according to VAS among the Group B (BTX-A) sneezing was 2.41 while 2.16 in Group F (fluticasone furoate). The difference is not statistically significant.

Conclusions: Intranasal injection of Botulinum A(BTX-A) is a highly effective, safe, and simple procedure, with lasting effect for one month in intermittent allergic rhinitis. It might be used in some patients with intermittent allergic rhinitis.

Keywords: Rhinitis, Allergic, Botox, Fluticasone. Read more